Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 3, pp 363–369 | Cite as

Prediction of mizoribine pharmacokinetic parameters by serum creatinine in renal transplant recipients

  • Pan Chen
  • Xuan Xu
  • Longshan Liu
  • Jingjing Wu
  • Jingjie Li
  • Qian Fu
  • Jie ChenEmail author
  • Changxi WangEmail author
Pharmacokinetics and Disposition
  • 102 Downloads

Abstract

Purpose

Mizoribine (MZR) is an immunosuppressive agent with extensive inter-individual differences in pharmacokinetics (PK). Here, we investigated the PK characteristics of MZR in renal transplant recipients and gave equations for prediction of some critical PK parameters.

Methods

A total of 40 renal transplant recipients participated in this prospective study and were administered MZR orally twice daily in the range of 1.1–8.9 mg kg−1 day−1. Steady-state concentrations of MZR were detected before (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, and 12 h after administration by high-performance liquid chromatography method. Another 38 patients with newly detected trough concentration (C0) were enrolled to validate the obtained C0 predictive equation.

Results

Significant inter-individual differences in MZR PK parameters were observed. Patients with decreasing creatinine clearance rate (CCr) had significantly decreased terminal elimination rate constant (kel) and apparent total body clearance (Cl/F), while other PK parameters including apparent terminal half-life (t1/2), peak time (Tmax), peak concentration (Cmax), area under the curve (AUC0-12h), apparent volume of distribution (V/F), and mean residence time (MRT) were significantly increased. Correlation coefficients between AUC0-12h and C0/Cmax were 0.894 and 0.916, respectively (both p < 0.001). A serum creatinine (SCr)-based predictive C0 equation [C0 = (2.160 × SCr − 54.473) × Dose] was established and validated by C0 from another 38 patients. Besides, significant linear correlations between kel/t1/2 and CCr were also found (r2 = 0.668 and 0.484, respectively), and equations predicting kel/t1/2 were also obtained (kel = 0.015 + 0.002 × CCr, t1/2 = 13.601 − 0.139 × CCr).

Conclusions

Renal function plays as an essential factor that contributes to great inter-individual MZR PK variation. Both C0 and Cmax are suitable for evaluating MZR exposure in the body. SCr could be applied to predict C0 and t1/2 of MZR.

Keywords

Mizoribine Renal transplantation Pharmacokinetics Immunosuppression 

Notes

Author contributions

Concept and design: Changxi Wang, Jie Chen

Acquisition of data: Longshan Liu, Qian Fu

Drug concentration determination: Jingjing Wu

Analysis and interpretation of the data: Pan Chen, Xuan Xu, Jingjie Li

Drafting of the article: Xuan Xu, Pan Chen

Critical review: All authors

Funding information

This study was financially supported by the National Natural Science Foundation of China (Grant: 81503156, 81601347), Natural Science Foundation of Guangdong Province (No. 2014A030310096), and Public Welfare Research and Capacity Building Fund of Guangdong (No. 2016A020218006).

Compliance with ethical standards

This study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sen University (approved no: 2015118) and informed consent was obtained from each enrolled patient

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Yokota S (2002) Mizoribine: mode of action and effects in clinical use. Pediatr Int 44(2):196–198CrossRefGoogle Scholar
  2. 2.
    Shi Y, Liu H, Chen XG, Shen ZY (2017) Comparison of mizoribine and mycophenolate mofetil with a tacrolimus-based immunosuppressive regimen in living-donor kidney transplantation recipients: a retrospective study in China. Transplant Proc 49(1):26–31.  https://doi.org/10.1016/j.transproceed.2016.10.018 CrossRefGoogle Scholar
  3. 3.
    Xing S, Yang J, Zhang X, Zhou P (2014) Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation--a meta-analysis. Clin Biochem 47(7–8):663–669.  https://doi.org/10.1016/j.clinbiochem.2014.01.014 CrossRefGoogle Scholar
  4. 4.
    Liu D, Kobayashi T, Nagasaka T, Yokoyama I, Ma Y, Miwa Y, Kuzuya T, Morozumi K, Oikawa T, Shimano Y, Takeuchi O, Uchida K, Nakao A (2005) Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection. Transpl Int 18(4):401–407.  https://doi.org/10.1111/j.1432-2277.2004.00042.x CrossRefGoogle Scholar
  5. 5.
    Naito T, Tokashiki S, Mino Y, Otsuka A, Ozono S, Kagawa Y, Kawakami J (2010) Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients. Basic Clin Pharmacol Toxicol 106(4):310–316.  https://doi.org/10.1111/j.1742-7843.2009.00489.x Google Scholar
  6. 6.
    Fukao M, Ishida K, Sakamoto T, Taguchi M, Matsukura H, Miyawaki T, Hashimoto Y (2011) Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males. Drug Metab Pharmacokinet 26(5):538–543CrossRefGoogle Scholar
  7. 7.
    Ishida K, Fukao M, Watanabe H, Taguchi M, Miyawaki T, Matsukura H, Uemura O, Zhang Z, Unadkat JD, Hashimoto Y (2013) Effect of salt intake on bioavailability of mizoribine in healthy Japanese males. Drug Metab Pharmacokinet 28(1):75–80CrossRefGoogle Scholar
  8. 8.
    Nagai T, Uemura O, Kaneda H, Ushijima K, Ohta K, Gotoh Y, Satomura K, Shimizu M, Fujieda M, Morooka M, Yamada T, Yamada M, Wada N, Hashimoto Y (2017) The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease. Clin Exp Nephrol 21(5):884–888.  https://doi.org/10.1007/s10157-016-1353-x CrossRefGoogle Scholar
  9. 9.
    Sugitani A, Kitada H, Ota M, Yoshida J, Doi A, Hirakata H, Tanaka M (2006) Revival of effective and safe high-dose mizoribine for the kidney transplantation. Clin Transpl 20(5):590–595.  https://doi.org/10.1111/j.1399-0012.2006.00522.x CrossRefGoogle Scholar
  10. 10.
    Fuke T, Abe Y, Hibino S, Takeshi M, Saito T, Sakurai S, Watanabe S, Murayama J, Itabashi K, Nakano Y (2012) Mizoribine requires individual dosing due to variation of bioavailability. Pediatr Int 54(6):885–891.  https://doi.org/10.1111/j.1442-200X.2012.03733.x CrossRefGoogle Scholar
  11. 11.
    Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, Teraoka S, Toma H, Ota K (1996) Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc 28(6):3643–3648Google Scholar
  12. 12.
    Stypinski D, Obaidi M, Combs M, Weber M, Stewart AJ, Ishikawa H (2007) Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol 63(4):459–468.  https://doi.org/10.1111/j.1365-2125.2006.02779.x CrossRefGoogle Scholar
  13. 13.
    Takada K, Asada S, Ichikawa Y, Sonoda T, Takahara S, Nagano S, Fukunishi T (1983) Pharmacokinetics of bredinin in renal transplant patients. Eur J Clin Pharmacol 24(4):457–461CrossRefGoogle Scholar
  14. 14.
    Ren B, Fu XH, Zhang ZH, Huang L, Wang CX, Chen X (2013) Determination of mizoribine in human plasma using high-performance liquid chromatography: application to a pharmacokinetic study in Chinese renal transplant recipients. Drug Res 63(7):376–381.  https://doi.org/10.1055/s-0033-1341499 CrossRefGoogle Scholar
  15. 15.
    Abe Y, Mikawa T, Fuke T, Hisano M, Tsuji Y, Watanabe S, Itabashi K (2008) Pharmacokinetic study of mizoribine in child-onset glomerulonephritis. Pediatr Int 50(5):615–619.  https://doi.org/10.1111/j.1442-200X.2008.02624.x CrossRefGoogle Scholar
  16. 16.
    Abe Y, Tsuji Y, Hisano M, Nakada M, Miura K, Watanabe S, Odajima Y, Iikura Y (2004) Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis. Pediatr Int 46(5):597–600.  https://doi.org/10.1111/j.1442-200x.2004.01936.x CrossRefGoogle Scholar
  17. 17.
    Kokado Y, Takahara S, Ishibashi M, Okuyama A (1994) Pharmacokinetics of mizoribine in renal transplant patients. Transplant Proc 26(4):2111–2113Google Scholar
  18. 18.
    Ihara H, Shinkuma D, Nojima M, Koike H, Yabumoto H, Yamanaka Y, Ikoma F (1994) Clinical significance of blood level monitoring of mizoribine in kidney transplantation. Transplant Proc 26(4):2029–2031Google Scholar
  19. 19.
    Zaoui P, Serre-Debeauvais F, Bayle F, Bessard G, Pintar P, Deteix P, Janbon B, Vialtel P (1995) Clinical use of mizoribine (Bredinin) and pharmacologic monitoring assessment in renal transplantation. Transplant Proc 27(1):1064–1065Google Scholar
  20. 20.
    Nishimura K, Uchida K, Yuzawa K, Fukuda Y, Ichikawa Y, Akioka K, Fujisawa M, Sugitani A, Ito S, Nakatani T, Horimi T, Yoshimura N (2012) Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients: multicenter study in Japan. Transplant Proc 44(1):147–149.  https://doi.org/10.1016/j.transproceed.2011.11.015 CrossRefGoogle Scholar
  21. 21.
    Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS (1991) Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 87(3):940–948.  https://doi.org/10.1172/JCI115101 CrossRefGoogle Scholar
  22. 22.
    Ihara H, Shinkuma D, Kubo M, Miyamoto I, Nojima M, Koike H, Yabumoto H, Ikoma F (1996) Influence of bioavailability on blood level of mizoribine in kidney transplant recipients. Transplant Proc 28(3):1321–1323Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacy, the First Affiliated HospitalSun Yat-sen UniversityGuangzhouPeople’s Republic of China
  2. 2.Organ Transplantation Center, the First Affiliated HospitalSun Yat-sen UniversityGuangzhouPeople’s Republic of China
  3. 3.Center of Reproductive Medicine, the Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhouChina

Personalised recommendations